Controversial liquid touted by biohackers may help hair grow — and prevent thinning caused by GLP-1s
A recent study suggests that methylene blue, a controversial liquid popular in biohacking, may promote hair growth and prevent thinning associated with GLP-1 medications. Researchers at the University of Maryland found that the substance boosts hair follicle stem cell growth and reduces oxidative stress. The findings indicate potential benefits for those experiencing hair loss as a side effect of weight loss drugs like semaglutide.
- ▪Methylene blue is being studied for its potential to support scalp health and hair growth.
- ▪The substance has shown promise in boosting hair follicle stem cell growth and survival in lab tests.
- ▪Users of GLP-1 medications have reported hair thinning as a side effect, which methylene blue may help address.
New York Post files mainly under news. We currently carry 10,965 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | New York Post |
| Canonical URL | https://nypost.com/2026/05/22/health/controversial-liquid-touted-by-biohackers-may-help-hair-grow/ |
| Publication time | Fri, 22 May 2026 13:11:53 -0400 |
| Retrieval time | 2026-05-22T17:17:02.716Z |
| Last seen | 2026-05-22T17:17:02.716Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | ce8so2SVRYKV |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Wellness Controversial liquid touted by biohackers may help hair grow — and prevent thinning caused by GLP-1s By McKenzie Beard Published May 22, 2026, 1:11 p.m. ET See more of our coverage in your search results. Add The New York Post on Google Balding might make you blue — but this news won’t. A recent study suggests that a controversial liquid popular in biohacking and wellness circles could support scalp health and hair growth. Researchers say the substance may even hold promise for GLP-1 users with thinning crowns, a frustrating side effect that’s become increasingly common as the blockbuster weight loss and diabetes drugs soar in popularity. 3 A drug already in use may help protect hair follicles from aging and stress, a new study found.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at New York Post.
Discussion
0 commentsMore from New York Post
